AstraZeneca COVID-19 vaccine: Authorization information

On this page

Market authorization with conditions

Health Canada authorized the AstraZeneca COVID-19 vaccine (ChAdOx1) for use for the COVID-19 pandemic. Authorization followed the interim order respecting the importation, sale and advertising of drugs for use in relation to COVID-19.

Due to the urgent public health needs relating to COVID-19, we can issue a market authorization with conditions to support early access to promising health products when the potential benefits outweigh the potential risks. In December, we published guidance to vaccine manufacturers regarding the evidence and documentation required to obtain a market authorization for a COVID-19 vaccine under the interim order.

Using the above regulatory pathway and evidence standards, the approval of the vaccine is supported by evidence that it is safe, effective and of high quality. Find detailed technical information about the AstraZeneca COVID-19 vaccine, such as the product monograph and our regulatory decision summary, in the COVID-19 vaccines and treatments regulatory portal.

According to the terms and conditions that Health Canada placed on the authorization, the manufacturers (AstraZeneca Canada Inc. and Verity Pharmaceuticals/Serum Institute of India (SII)) will submit to Health Canada:

Risk management plan

Companies are required to submit a risk management plan (RMP) to Health Canada when applying for any marketing authorization.

RMPs include information on:

Health Canada reviewed the RMPs for the AstraZeneca COVID-19 vaccines and found them to be acceptable.

International considerations

In addition to working with the Public Health Agency of Canada and provinces and territories, Health Canada also exchanges information with our international regulatory counterparts on an ongoing basis. This collaboration helps to support the review process and post-market safety monitoring activities.

We will continue to actively monitor and review all relevant data to determine whether changes to the market authorization of the AstraZeneca COVID-19 vaccine in Canada are required.

Related links

Did you find what you were looking for?

What was wrong?

You will not receive a reply. Telephone numbers and email addresses will be removed.
Maximum 300 characters

Thank you for your feedback

Date modified: